JP2022500470A5 - - Google Patents
Info
- Publication number
- JP2022500470A5 JP2022500470A5 JP2021515030A JP2021515030A JP2022500470A5 JP 2022500470 A5 JP2022500470 A5 JP 2022500470A5 JP 2021515030 A JP2021515030 A JP 2021515030A JP 2021515030 A JP2021515030 A JP 2021515030A JP 2022500470 A5 JP2022500470 A5 JP 2022500470A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- cycloalkyl
- haloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732590P | 2018-09-18 | 2018-09-18 | |
| US62/732,590 | 2018-09-18 | ||
| PCT/US2019/051274 WO2020060915A1 (en) | 2018-09-18 | 2019-09-16 | Cyclopentyl acids as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500470A JP2022500470A (ja) | 2022-01-04 |
| JP2022500470A5 true JP2022500470A5 (enExample) | 2023-11-08 |
| JP7427658B2 JP7427658B2 (ja) | 2024-02-05 |
Family
ID=68073223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515030A Active JP7427658B2 (ja) | 2018-09-18 | 2019-09-16 | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12209072B2 (enExample) |
| EP (1) | EP3852746B1 (enExample) |
| JP (1) | JP7427658B2 (enExample) |
| KR (1) | KR102950123B1 (enExample) |
| CN (1) | CN113473985A (enExample) |
| ES (1) | ES2946657T3 (enExample) |
| WO (1) | WO2020060915A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| ES2948793T3 (es) * | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022034568A1 (en) * | 2020-08-11 | 2022-02-17 | Viva Star Biosciences Limited | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
| CN117751106A (zh) * | 2021-04-30 | 2024-03-22 | 唯久生物技术(苏州)有限公司 | 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 |
| WO2022240879A1 (en) * | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| JP2024525679A (ja) * | 2021-07-20 | 2024-07-12 | 上海拓界生物医薬科技有限公司 | Ｌｐａ１低分子拮抗薬 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| JP2026505734A (ja) * | 2023-01-19 | 2026-02-18 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | トリアゾール系化合物の薬用可能な塩、結晶型及びその調製方法 |
| WO2025051267A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
| KR20130126659A (ko) | 2010-12-07 | 2013-11-20 | 아미라 파마슈티칼스 인코포레이티드 | 리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도 |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| IN2014DN09352A (enExample) | 2012-06-20 | 2015-07-17 | Hoffmann La Roche | |
| JP2015520202A (ja) | 2012-06-20 | 2015-07-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物 |
| WO2014130241A1 (en) * | 2013-02-20 | 2014-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| WO2014145873A2 (en) | 2013-03-15 | 2014-09-18 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP3728209B1 (en) | 2017-12-19 | 2025-12-24 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| JP7299892B2 (ja) | 2017-12-19 | 2023-06-28 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン |
| JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
| US11261180B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as LPA antagonists |
| ES2898364T3 (es) | 2017-12-19 | 2022-03-07 | Bristol Myers Squibb Co | Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| EP3728216B1 (en) | 2017-12-19 | 2023-09-06 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| ES2948793T3 (es) | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
-
2019
- 2019-09-16 ES ES19779299T patent/ES2946657T3/es active Active
- 2019-09-16 US US17/276,176 patent/US12209072B2/en active Active
- 2019-09-16 CN CN201980074355.6A patent/CN113473985A/zh active Pending
- 2019-09-16 WO PCT/US2019/051274 patent/WO2020060915A1/en not_active Ceased
- 2019-09-16 JP JP2021515030A patent/JP7427658B2/ja active Active
- 2019-09-16 EP EP19779299.7A patent/EP3852746B1/en active Active
- 2019-09-16 KR KR1020217011087A patent/KR102950123B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500470A5 (enExample) | ||
| JP2022500469A5 (enExample) | ||
| JP2022500473A5 (enExample) | ||
| JP2021508686A5 (enExample) | ||
| JP2021507895A5 (enExample) | ||
| JP2021506878A5 (enExample) | ||
| JP2021507896A5 (enExample) | ||
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2021507900A5 (enExample) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2019518766A5 (enExample) | ||
| CN103443098B (zh) | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 | |
| JP6534675B2 (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2020528889A5 (enExample) | ||
| JP2023544476A5 (enExample) | ||
| JP6824954B2 (ja) | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール | |
| JP2019530669A5 (enExample) | ||
| JP6824952B2 (ja) | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール | |
| JP2011523945A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP7683930B2 (ja) | セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用 | |
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| JP6830909B2 (ja) | ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール | |
| JP2008513498A5 (enExample) | ||
| JP2017511794A5 (enExample) |